A multicentre, open-label phase II study of irinotecan, capecitabine, and oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
2016 ◽
Vol 34
(15_suppl)
◽
pp. 4032-4032
Keyword(s):
Phase Ii
◽
2017 ◽
Vol 79
(4)
◽
pp. 813-823
◽
Keyword(s):
2011 ◽
Keyword(s):